Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 15Terminated 7Recruiting 4Unknown 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 6Plasma cell 2Myeloid 1Head & Neck 1Dermatologic 1Classical hematology 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Methylprednisolone × Plasma cell × Clear all
NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡